An ongoing dialogue on HIV/AIDS, infectious diseases,
July 3rd, 2016
Velpatasvir/Sofosbuvir Makes HCV Treatment Simpler, Especially For Genotypes 2 and 3
One of the ways ID and hepatology hepatitis C experts like to show off is by discoursing on the nuances of cleverly named clinical trials, and how these impact treatment guidelines. It usually goes something like this: “In the EP-CILEON [I made that up] study of [insert HCV regimen here], treatment-experienced patients with genotype [insert non-genotype 1 patients here, […]
June 12th, 2016
Progress in Lyme Disease Badly Needed — Could a “Hackathon” Help?
Someone recently asked what keeps me, a specialist in Infectious Diseases, up at night. With the admission that I do all my clinical work here in the USA — a person working in the tropics would undoubtedly have a different list — several challenging patient care and public health issues came to mind. Multidrug-resistant bacteria. Endovascular infections in […]
April 2nd, 2016
You Too Can Have Fun with Academic Spam
Like most doctors who work at academic medical centers, I get a fair amount of “academic spam” — invitations to bogus meetings that take place in some exotic or at least warm place (China, Dubai, and Orlando are favorites), efforts to sell me monoclonal antibodies or, more recently, CRISPR-altered mice, and of course requests to contribute research papers or […]
March 27th, 2016
One-Week-to-Baseball ID Link-o-Rama
(Important note: Title has nothing to do with this post’s content. I just felt like writing something about baseball.) As some of us eagerly await the start of the 2016 baseball season — especially Cubs fans — here are some ID/HIV items yearning to shag flies, toss around the horsehide, and play some pepper: Famous anti-vaxxer — and notorious scientific fraud — […]
March 15th, 2016
Dogs Again Are Brilliant Diagnosticians
The reputation of dogs in the ID world got a big boost when Dutch researchers published this remarkable study of Cliff — a beagle who was trained to “diagnose” C diff using his superior olfactory abilities. (A couple of entertaining videos here, if you can’t get enough of this stuff. I can’t.) Now, in the pages of Open Forum Infectious Diseases (IDSA’s […]
March 9th, 2016
Approval of TAF/FTC/RPV, Another Single Pill HIV Treatment Option
The approval last week of TAF/FTC/RPV — that’s coformulated tenofovir alafenamide, emtricitabine, and rilpivirine — brings us another one-pill, once-daily option for HIV treatment. It’s essentially the same as the existing TDF/FTC/RPV, with similar pros/cons, but with three notable differences coming with the substitution of TAF for TDF. Specifically: Likely reduced renal and bone toxicity. Since approval was based on bioequivalnce, this hasn’t […]
January 18th, 2016
IV and Injectable HIV Treatments Are Much Discussed — But Won’t Be Here Anytime Soon
Something interesting happens when you poll people who treat HIV — and people who have HIV — about whether they’d prefer a treatment option that consists of a periodic injection or infusion in place of the pill or pills that they take every day. Lots of them say yes. Even people who are taking just one pill […]
November 29th, 2015
Flu Vaccine Keeps Taking Hits, Still the Best We’ve Got — Don’t Stop “Belivin'” [sic]
For reasons understood only by the geniuses in Mountain View, CA, for some reason my Google news feed picked up this bit of “scientific” reporting: Let me allow the author, an unfortunately named “Clapway” (gonorrhea researcher?), to speak for him/herself: However, is the flu vaccine really worth it? The author of this article never takes it and […]
November 26th, 2015
Five (OK, Six) ID/HIV Things to be Grateful for this Holiday Season, 2015 Edition
Some quick ID/HIV gratitude items for 2015, done rapidly as we’re hosting a big meal later today. I wonder what that might be. New Ebola virus disease cases and deaths have dramatically declined. I write that sentence with some trepidation, as cases continue to occur sporadically, and this late relapse in a nurse was a chilling reminder of […]
November 18th, 2015
Are There Remaining Challenges in HCV Therapy?
Prompted by (yet more) spectacular HCV study results, I posted the following questions on Twitter: Is velpatasvir/sofosbuvir the endgame for HCV? And what will HCV researchers do now? https://t.co/vL2A9FOttR @NEJM — Paul Sax (@PaulSaxMD) November 18, 2015 To which I got this reply from one of our very energetic second-year ID fellows: @PaulSaxMD @NEJM what about coinfected patients, […]